$TTRX

WBB Securities upgraded Turn Therapeutics (TTRX) to Hold from Sell, setting a $10.00 price target. The stock has fallen from $16.45 but is up over 200% in six months. WBB expects Phase 2 trial results in 2026, but sees challenges for small-cap life science firms. Lucid Capital Markets initiated coverage with a Buy rating and $24.00 target, citing GX-03's potential.

Turn Therapeutics updated its investor presentation, highlighting GX-03 clinical progress and a $10.3M cash balance as of June 30, 2026. The company expects Phase 2 topline results for atopic dermatitis in Q1 2027 and has a cash runway into Q3 2027. Key milestones include an FDA meeting in Q4 2026 and Phase 3 initiations in 2027. The presentation also details safety and efficacy signals, financials, and IP status.

Lucid Capital Markets initiated coverage of Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and $24.00 price target, citing 77% upside. The company's GX-03 drug is in Phase 2 trials for atopic dermatitis, with results expected in 2026. TTRX stock has risen 305% in the past six months.

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per s

Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low

Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).

Turn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.

Turn Therapeutics (TTRX) reported interim Phase 2 data for GX-03 in 50 adults with moderate-to-severe atopic dermatitis. According to the company, 92.6% of GX-03 patients achieved EASI-50 at Week 4 vs 65.2% with vehicle; EASI-90 was 44.4% vs 30.4% at Week 4 and 51.9% vs 34.8% at Week 8. No treatment-related serious adverse events were reported.

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.

Turn Therapeutics has secured up to $25 million in growth capital financing from Avenue Capital Group to advance its clinical programs for atopic dermatitis and onychomycosis, with an immediate $7 million tranche. The funding is expected to extend the company's financial runway through the mid-year readout of its Phase 2 trial for atopic dermatitis and support preparations for registrational trials of its lead asset, GX-03. Additional funds are contingent on achieving specific clinical and corporate milestones.